Close Menu

NEW YORK (GenomeWeb) – Oppenheimer has initiated coverage of Genomic Health with a rating of Perform, calling the company a leader in diagnostic testing. The investment bank also initiated coverage of Invitae with a rating of Outperform and a $21 12- to 18-month price target, noting that the company will benefit from several growth trends in the genetic testing sector.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.